Glycosylated Hemoglobin and C-Peptide Market Size | COVID-19 Impact Analysis | Forecast to 2027

The global glycosylated hemoglobin and C-peptide market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Glycosylated Hemoglobin and C-Peptide is also known as glycosylated hemoglobin blood test. It is used to measure blood glucose levels over the past 3 months. Additionally, glycosylated hemoglobin refers to a hemoglobin molecule that is bound to glucose. Further, C-peptide connects two chains of the insulin molecule. The major factor driving the demand for the global glycosylated hemoglobin and C-peptide market during the forecast period is the increasing prevalence of diabetes across the globe.

According to the International Diabetes Federation (IDF), in 2021, approximately 537 million adults aged 20-79 years has diabetes globally with 3 in 4 adults with diabetes living in low- and middle-income countries with a mortality rate of 6.7 million people globally. Additionally, the total number of people living with diabetes is anticipated to rise to 643 million by 2030 and 783 million by 2045. Moreover, almost 1 in 2 (240 million) adults living with diabetes are undiagnosed. Hence, the increasing prevalence of diabetes is increasing the demand for glycosylated hemoglobin and C-peptide to test the measures your insulin levels which in turn is driving the growth of the market.

To Request a Sample of our Report on Glycosylated Hemoglobin and C-Peptide Market: https://www.omrglobal.com/request-sample/glycosylated-hemoglobin-and-c-peptide-market

Some major players in the market include Pfizer Inc., Sanofi S.A., and Novartis International AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in September 2021, LeaderMed Health Group Ltd. announced a joint venture with OPKO Health, Inc. The joint venture was aimed to develop, manufacture and commercialize two of OPKO's clinical stage, long-acting drug products including OPK88003 and Factor VIIa-CTP in Greater China and eight other Asian territories.

Market Coverage

The market number available for - 2020-2027

Base year- 2020

Forecast period- 2021-2027

Segment Covered-

· By Type

· By Applications

Regions Covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape- Pfizer Inc., Sanofi S.A., and Novartis International AG, among others.

(Get 15% Discount on Buying this Report)

A full Report of Glycosylated Hemoglobin and C-Peptide Market is Available @ https://www.omrglobal.com/industry-reports/glycosylated-hemoglobin-and-c-peptide-market

Global Glycosylated Hemoglobin And C-Peptide Market Report by Segment

By Type

· Capsule

· Tablet

· Others

By Application

· Oncology

· Diabetes

· Blood Disorder

· Others

Global Glycosylated Hemoglobin And C-Peptide Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.